Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3617787
Max Phase: Preclinical
Molecular Formula: C36H49N7O18
Molecular Weight: 867.82
Molecule Type: Protein
Associated Items:
ID: ALA3617787
Max Phase: Preclinical
Molecular Formula: C36H49N7O18
Molecular Weight: 867.82
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O
Standard InChI: InChI=1S/C36H49N7O18/c1-17(44)30(35(59)37-16-25(46)39-20(8-11-26(47)48)31(55)42-24(36(60)61)14-19-6-4-3-5-7-19)43-33(57)22(10-13-28(51)52)40-32(56)21(9-12-27(49)50)41-34(58)23(15-29(53)54)38-18(2)45/h3-7,17,20-24,30,44H,8-16H2,1-2H3,(H,37,59)(H,38,45)(H,39,46)(H,40,56)(H,41,58)(H,42,55)(H,43,57)(H,47,48)(H,49,50)(H,51,52)(H,53,54)(H,60,61)/t17-,20+,21+,22+,23+,24+,30+/m1/s1
Standard InChI Key: ZXBJGVKYUXGMIU-WYPAPEJYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 867.82 | Molecular Weight (Monoisotopic): 867.3134 | AlogP: -4.19 | #Rotatable Bonds: 28 |
Polar Surface Area: 410.43 | Molecular Species: ACID | HBA: 13 | HBD: 13 |
#RO5 Violations: 3 | HBA (Lipinski): 25 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.16 | CX Basic pKa: | CX LogP: -5.22 | CX LogD: -21.21 |
Aromatic Rings: 1 | Heavy Atoms: 61 | QED Weighted: 0.04 | Np Likeness Score: 0.10 |
1. Bertrand HC, Schaap M, Baird L, Georgakopoulos ND, Fowkes A, Thiollier C, Kachi H, Dinkova-Kostova AT, Wells G.. (2015) Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction., 58 (18): [PMID:26348784] [10.1021/acs.jmedchem.5b00602] |
2. Li Q, Xing S, Chen Y, Liao Q, Li Q, Liu Y, He S, Feng F, Chen Y, Zhang J, Liu W, Guo Q, Sun Y, Sun H.. (2020) Reasonably activating Nrf2: A long-term, effective and controllable strategy for neurodegenerative diseases., 185 [PMID:31735576] [10.1016/j.ejmech.2019.111862] |
3. Mou Y, Wen S, Li YX, Gao XX, Zhang X, Jiang ZY.. (2020) Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors., 202 [PMID:32668381] [10.1016/j.ejmech.2020.112532] |
Source(1):